Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Recommendation of “Hold” from Brokerages

Posted by Brian Himes on Aug 24th, 2026

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given a consensus rating of “Hold” by the seven research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $4.75.

IPSC has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Finally, Mizuho started coverage on Century Therapeutics in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 target price on the stock.

Read Our Latest Report on Century Therapeutics

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IPSC. Bank of America Corp DE raised its stake in shares of Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after purchasing an additional 34,466 shares during the last quarter. AQR Capital Management LLC boosted its position in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after buying an additional 86,875 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Century Therapeutics by 26.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock worth $86,000 after buying an additional 38,052 shares during the period. Acadian Asset Management LLC increased its holdings in Century Therapeutics by 101.2% in the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock worth $133,000 after buying an additional 142,953 shares during the period. Finally, Prudential Financial Inc. purchased a new position in Century Therapeutics during the 2nd quarter worth approximately $25,000. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Trading Up 2.2%

Shares of IPSC stock traded up $0.04 during trading hours on Monday, reaching $2.12. 119,647 shares of the company’s stock were exchanged, compared to its average volume of 1,389,911. Century Therapeutics has a 1 year low of $0.44 and a 1 year high of $3.04. The stock has a market cap of $382.96 million, a PE ratio of -2.27 and a beta of 1.57. The stock’s fifty day moving average price is $2.18 and its two-hundred day moving average price is $2.21.

Century Therapeutics (NASDAQ:IPSC – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.06). On average, equities analysts expect that Century Therapeutics will post -0.47 EPS for the current fiscal year.

About Century Therapeutics

(Get Free Report)

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.